Related Experiment Video
Updated: Oct 17, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma]
1Department of General Surgery,Huzhou Hospital,College of Medicine,Zhejiang University,Huzhou 313003,Zhejiang Province,China.
Abstract:
Hepatocellular carcinoma(HCC) is one of the most common malignant tumors of the digestive system in the clinic. In recent years, the proposal and development of immunotherapy have set off a worldwide anticancer upsurge. In particular, programmed death receptor 1(PD-1) and programmed death receptor ligand 1(PD-L1) inhibitor have been used in a wide variety of tumor diseases and achieved good curative effect. However, the application of PD-1 or PD-L1 inhibitors in HCC is mostly still at the stage of clinical trials, and some clinical trials have shown gratifying results in patients with advanced HCC and postoperative recurrence. More studies have shown that PD-1 or PD-L1 inhibitors combined with radiofrequency, chemoradiotherapy, and molecular targeted drugs can bring greater benefits to patients.
Insights
Immunotherapy, particularly programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand (PD-L1) inhibitors, shows promise for treating hepatocellular carcinoma (HCC). Combinations with other therapies may enhance benefits for advanced or recurrent HCC patients.
Area of Science:
- Oncology
- Immunotherapy
- Hepatocellular Carcinoma Research
Background:
- Hepatocellular carcinoma (HCC) is a prevalent digestive system malignancy.
- Immunotherapy, especially targeting the PD-1/PD-L1 pathway, has revolutionized cancer treatment.
- PD-1/PD-L1 inhibitors are approved for various cancers but are largely in clinical trials for HCC.
Purpose of the Study:
- To review the current status and potential of PD-1/PD-L1 inhibitors in HCC treatment.
- To explore the efficacy of combination therapies involving PD-1/PD-L1 inhibitors for HCC.
Main Methods:
- Review of clinical trial data and scientific literature on PD-1/PD-L1 inhibitors in HCC.
- Analysis of treatment outcomes in patients with advanced or recurrent HCC.
- Evaluation of combination strategies (e.g., with radiofrequency, chemoradiotherapy, targeted drugs).
Main Results:
- Clinical trials indicate promising results for PD-1/PD-L1 inhibitors in advanced and recurrent HCC.
- Combination therapies involving PD-1/PD-L1 inhibitors demonstrate potential for improved patient benefits.
Conclusions:
- PD-1/PD-L1 inhibitors represent a significant advancement in HCC treatment strategies.
- Further research and clinical trials are warranted to optimize the use of these inhibitors, particularly in combination regimens, for HCC patients.
